Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference

Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First
Boston Healthcare Conference 


CAMBRIDGE, Mass., and SAN DIEGO, Nov. 11  /PRNewswire-FirstCall/ -- Biogen, Inc.
 and IDEC Pharmaceuticals Corporation  announced today that IDEC's Chairman and
Chief Executive Officer, William H. Rastetter, Ph.D., and Biogen's Chief
Financial Officer, Peter Kellogg, will make a presentation at the Credit Suisse
First Boston Healthcare Conference on Thursday, November 13, 2003 at 9:00 a.m.
Mountain Time (MT) at The Arizona Biltmore Resort in Phoenix, Arizona.

(Logo:  http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )

Assuming the merger between IDEC and Biogen is approved by shareholders at
Special Meetings on Wednesday, November 12, held in San Diego and Cambridge,
respectively, Mr. Rastetter and Mr. Kellogg would give a presentation about the
new Biogen Idec.

The presentation will be webcast live and is accessible by using the link
provided in the investor relations section of Biogen's (http://www.biogen.com/)
and IDEC's (http://www.idecpharm.com/) websites.

About Biogen

Biogen is the world's oldest independent biotechnology company and a leader in
biologics research, development and manufacturing. A pioneer in leading edge
research in immunology, neurobiology and oncology, Biogen brings novel therapies
to improve patients' lives around the world through its global marketing
capabilities.

About IDEC Pharmaceuticals

IDEC is a leader in the discovery, development, and commercialization of
targeted immunotherapies for the treatment of cancer and autoimmune diseases.
IDEC discovered and developed the first commercially available
radioimmunotherapy product (Zevalin(R)) approved in the United States, which is
used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and, with
co-promotion partner Genentech, Inc., developed the first monoclonal antibody
product (Rituxan(R)) approved in the United States for the treatment of cancer.
Rituxan is approved in over 70 countries worldwide and is also used to treat
various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based, integrated
biopharmaceutical company with multiple products in clinical stage development
and strategic alliances in a variety of research platforms.

   Contact:
   Rob Jacobson
   Investor Relations Specialist
   Biogen, Inc.
   617/679-3710


http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO

http://photoarchive.ap.org/

DATASOURCE: Biogen, Inc.



CONTACT:  Rob Jacobson, Investor Relations Specialist of Biogen,

[phone]



Web site:  http://www.biogen.com/

http://www.idecpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/101550.html

Copyright